Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
RESEARCH TOOLSreports
Holding BCYC?
Track your performance easily
BCYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.31 - $28.67
Previous Close$20.36
Volume581.51K
Average Volume (3M)434.21K
Market Cap
$1.38B
Enterprise Value$489.69M
Total Cash (Recent Filing)$961.40M
Total Debt (Recent Filing)$37.64M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Mar 04, 2025EPS Estimate
-$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.30
Shares Outstanding69,046,021
10 Day Avg. Volume408,346
30 Day Avg. Volume434,206
Standard Deviation0.17
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.69
Price to Sales (P/S)38.32
Price to Cash Flow (P/CF)-8.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.37
Enterprise Value/Gross Profit18.15
Enterprise Value/Ebitda-3.18
Forecast
1Y Price Target
$39.10Price Target Upside96.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bicycle Therapeutics News
PremiumCompany Announcements
Bicycle Therapeutics: Promising Q3 Results and Business Progress
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe favorable safety profiles exhibited for both zelenectide pevedotin and BT5528 to date provide promising opportunities for combination therapies.
Financial PositionBicycle has a strong cash position of $961.4MM, providing financial stability and opportunities for growth.
Partnerships And CollaborationsMultiple partnerships provide non-dilutive capital and external pipeline validation, enhancing the company's prospects.
Bears Say
EarningsThe company reported revenues of $2.7M, significantly below the consensus estimate of $6.8M, indicating a major earnings shortfall.
Financial PerformanceLower royalty revenue combined with higher operating expenses has negatively impacted the company's financial performance.
Pipeline UpdatesThe recent earnings release lacked new updates on the company's key pipeline assets, which may concern investors looking for progress.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Bicycle Therapeutics Ltd lowest stock price was $13.31 and its highest was $28.67 in the past 12 months.
What is Bicycle Therapeutics Ltd’s market cap?
Currently, no data Available
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2025 which is in 103 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on Oct 31, 2024. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.797 by $0.057.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -$0.85.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Bicycle Therapeutics Ltd has 47,553,920 shares outstanding.
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.797. Following the earnings report the stock price went down -2.455%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Among the largest hedge funds holding Bicycle Therapeutics Ltd’s share is Baker Bros Advisors LP. It holds Bicycle Therapeutics Ltd’s shares valued at 213M.
---
Bicycle Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.10 (96.48% Upside)
$39.10 (96.48% Upside)
Blogger Sentiment
Bullish
BCYC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
49.37%
12-Months-Change
Fundamentals
Return on Equity
-26.82%
Trailing 12-Months
Asset Growth
56.06%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
---
BCYC Stock 12 Month Forecast
Average Price Target
$39.10
▲(96.48% Upside)
Technical Analysis
Best Analysts Covering BCYC
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+26.21%
reiterated a buy rating 29 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +26.21% per trade.
---